{
    "pmcid": "11100608",
    "summary": "The paper titled \"Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern\" explores the development of bispecific antibodies (bsAbs) targeting the SARS-CoV-2 spike protein, specifically focusing on the N-terminal domain (NTD) and receptor binding domain (RBD). The study addresses the challenge posed by the emergence of SARS-CoV-2 variants of concern (VOCs) that have reduced the effectiveness of existing antibody therapeutics.\n\n### Key Insights on SARS-CoV-2 Spike Protein and Nanobody Design:\n\n1. **Spike Protein Structure and Function:**\n   - The SARS-CoV-2 spike protein is a trimeric glycoprotein composed of S1 and S2 subunits. The S1 subunit contains the NTD and RBD, which are critical for viral entry into host cells.\n   - The RBD is the primary target for neutralizing antibodies due to its role in binding to the ACE2 receptor on host cells. However, mutations in the RBD, particularly in VOCs like Omicron, have led to reduced efficacy of RBD-targeting antibodies.\n\n2. **NTD and RBD Targeting:**\n   - The study highlights the potential of targeting the NTD, particularly non-supersite epitopes, to overcome the limitations of RBD-targeting antibodies. The NTD-specific antibody C1596 was identified as having broad binding specificity and neutralization potency against various VOCs, including Omicron variants.\n   - Structural analysis using cryo-EM revealed that C1596 binds to a distinct NTD epitope outside the site i antigenic supersite, which is less prone to mutations, making it a promising candidate for broad-spectrum neutralization.\n\n3. **Bispecific Antibody Design:**\n   - The researchers engineered bispecific antibodies (CoV2-biRNs) combining NTD-specific C1596 with RBD-specific antibodies. This dual targeting approach aims to enhance neutralization potency and breadth by engaging multiple spike epitopes.\n   - Two bispecific constructs, CoV2-biRN5 and CoV2-biRN7, demonstrated potent neutralization against all tested Omicron variants, including XBB.1.5, EG.5.1, and BA.2.86, outperforming the parental antibodies used alone or in cocktails.\n\n4. **Mechanism of Action:**\n   - The bispecific antibodies leverage the structural insights of C1596 binding to stabilize the spike protein in a conformation that facilitates RBD targeting by the second antibody arm. This strategy enhances intraspike avidity and cross-linking, contributing to their robust neutralization capabilities.\n\n5. **Therapeutic Potential and Resilience:**\n   - The study underscores the potential of NTD-RBD bispecific antibodies as next-generation therapeutics that can withstand viral evolution. The broad and potent neutralization profile of CoV2-biRN5 and CoV2-biRN7 suggests their utility in prophylactic and therapeutic applications against emerging SARS-CoV-2 variants.\n   - The low prevalence of escape mutations in circulating strains further supports the resilience of these bispecific antibodies, indicating minimal selective pressure on the targeted epitopes.\n\n6. **Implications for Nanobody Design:**\n   - The findings highlight the importance of targeting conserved and less mutable regions of the spike protein for designing effective nanobody binders. By focusing on non-supersite NTD epitopes and combining them with RBD-targeting strategies, nanobodies can achieve broad-spectrum neutralization.\n   - The structural insights provided by cryo-EM can guide the rational design of nanobodies with optimized binding kinetics and enhanced stability, crucial for developing robust antiviral therapeutics.\n\nIn conclusion, the study presents a compelling case for the use of bispecific antibodies targeting both the NTD and RBD of the SARS-CoV-2 spike protein. By leveraging structural insights and focusing on conserved epitopes, these bispecific constructs offer a promising approach to counteract the challenges posed by viral evolution and the emergence of new variants. The research provides valuable guidance for the design of nanobody binders with broad and potent neutralization capabilities against SARS-CoV-2.",
    "title": "Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern"
}